AQAnne Marie Queenan

Anne Marie Queenan

*This is an algorithmically generated author record based on publicly available information.

Anne Marie Queenan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Karen Bush

    The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869,1 and The Mount Sinai Hospital, New York, New York 100292

    2 shared publications
  • Antone A. Medeiros

    <!--label omitted: 6-->Miriam Hospital, Brown University, Providence, Rhode Island 029066

    1 shared publication
  • Carlos Torres-Viera

    <!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and

    1 shared publication
  • George M. Eliopoulos

    <!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and

    1 shared publication
  • Howard S. Gold

    <!--label omitted: 2-->Beth Israel Deaconess Medical Center2 and

    1 shared publication
  • Janet Hindler

    <!--label omitted: 5-->University of California at Los Angeles Medical Center, Los Angeles, California 900245; and

    1 shared publication

Latest Publications

  • Open Access

    Cloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded β-Lactamase from a New York City Klebsiella pneumoniae Clinical Isolate

    by Anne Marie Queenan, Stephen Jenkins, Karen Bush

    Klebsiella pneumoniae 5064, isolated in New York, carried plasmid-mediated resistance to multiple β-lactams and was unresponsive to clavulanic acid. The β-lactamase gene responsible for cephalosporin resistance encoded FOX-5, with 96 to 97% amino acid identities to other members of the FOX family of β-lactamases. The bla FOX-5 coding region was located next to a transposase gene from the Aeromonas salmonicida insertion element IS AS2 .


  • SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens Strains

    by Anne Marie Queenan, Carlos Torres-Viera, Howard S. Gold, Yehuda Carmeli, George M. Eliopoulos, Robert C. Moellering, John P. Quinn, Janet Hindler, Antone A. Medeiros, Karen Bush

    Three sets of carbapenem-resistant Serratia marcescens isolates have been identified in the United States: 1 isolate in Minnesota in 1985 (before approval of carbapenems for clinical use), 5 isolates in Los Angeles (University of California at Los Angeles [UCLA]) in 1992, and 19 isolates in Boston from 1994 to 1999. All isolates tested produced two β-lactamases, an AmpC-type enzyme with pI values of 8.6 to 9.0 and one with a pI value of approximately 9.5. The enzyme with the higher pI in each strain hydrolyzed carbapenems and was not inhibited by EDTA, similar to the chromosomal class A SME-1 β-lactamase isolated from the 1982 London strain S. marcescens S6. The genes encoding the carbapenem-hydrolyzing enzymes were cloned in Escherichia coli and sequenced. The enzyme from the Minnesota isolate had an amino acid sequence identical to that of SME-1. The isolates from Boston and UCLA produced SME-2, an enzyme with a single amino acid change relative to SME-1, a substitution from valine to glutamine at position 207. Purified SME enzymes from the U.S. isolates had β-lactam hydrolysis profiles similar to that of the London SME-1 enzyme. Pulsed-field gel electrophoresis analysis revealed that the isolates showed some similarity but differed by at least three genetic events. In conclusion, a family of rare class A carbapenem-hydrolyzing β-lactamases first described in London has now been identified in S. marcescens isolates across the United States.